August 2, 2007
GTC partners with French lab
By Cory Hopkins
GTC Biotherapeutics Inc. of Framingham and French biotech lab LFB have begun joint development of a new antibody for oncology and auto-immune conditions.
The new CD20 antibody is expected to be similar to LFB's current Rituximab product, which had worldwide sales of nearly $4 billion in 2006. Existing relevant CD20 antibody patents will expire by 2014, the companies said.
Production of the antibody in the milk of transgenic goats is expected to begin in 2008, with an investigational new drug application to the FDA planned for 2010.
The new CD20 antibody is expected to be similar to LFB's current Rituximab product, which had worldwide sales of nearly $4 billion in 2006. Existing relevant CD20 antibody patents will expire by 2014, the companies said.
Production of the antibody in the milk of transgenic goats is expected to begin in 2008, with an investigational new drug application to the FDA planned for 2010.
WBJ Web Partners
Most Recent
Most Recent
0 Comments